NLRP3 and familial Mediterranean fever: Canakinumab is FDA-approved for adult and childhood Still’s disease, Cryopyrin-Associated Periodic Fever Syndromes (CAPS, including NOMID), Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS), and Familial Mediterranean Fever (FMF).